Skip to content

News & Presentations

Press Releases

Q32 Bio Announces Publication of Preclinical Data in Molecular Therapy Demonstrating the Therapeutic Potential of Tissue-Targeted Complement Inhibitor ADX-097 for Complement-Mediated Diseases

— Novel approach to directly target local tissue complement dysregulation resulted in durable and efficacious complement blockade without systemic inhibition in preclinical studies — — Company is planning to evaluate ADX-097 in a Phase 2 clinical trial of complement-mediated renal diseases, with initial data expected by year-end 2024 and topline results in 2025, and a […]

Q32 Bio and Homology Medicines Announce Merger Agreement

–The combined company will operate as Q32 Bio Inc., advancing the development of Q32 Bio’s two clinical development candidates, bempikibart (ADX-914) in Phase 2 for the treatment of atopic dermatitis (AD) and alopecia areata (AA), and ADX-097 entering Phase 2 for the treatment of complement disorders– –Q32 Bio has re-acquired worldwide development and commercial rights […]

Q32 Bio Regains Worldwide Rights to Bempikibart (ADX-914) from Amgen

— Q32 Bio now wholly owns development and commercialization rights to the anti-IL-7Rα antibody, currently being evaluated in two Phase 2 trials for atopic dermatitis (AD) and    alopecia areata (AA) — — Re-acquisition bolsters Q32 Bio’s autoimmune product portfolio and broadens strategic opportunities — WALTHAM, Mass. – Nov. 16, 2023 — Q32 Bio, a clinical stage biotechnology […]

Q32 Bio Appoints Saul Fink, Ph.D. as Chief Technology Officer

Waltham, Mass. – October 24, 2023 — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced the appointment of Saul Fink, Ph.D., as Chief Technology Officer. Dr. Fink will be responsible for all aspects of Q32 Bio’s chemistry, manufacturing and control (CMC)-related activities. “We are thrilled to welcome Saul to […]

Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia Areata

Alopecia areata is the second autoimmune indication being evaluated for bempikibart WALTHAM, Mass., and DUBLIN – September 13, 2023 — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Nasdaq: HZNP), today announced that the first patient has been dosed in a randomized, double-blind, placebo-controlled, Phase 2 multicenter, proof-of-concept study […]

Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of ADX-914 for Atopic Dermatitis

WALTHAM, Mass., and DUBLIN  – October 27, 2022 — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Nasdaq: HZNP), today announced that the first patient has been dosed in a randomized, double-blind, placebo-controlled, Phase 2 multi-center proof-of-concept study in adult subjects to evaluate the safety and efficacy of ADX-914 […]

Q32 Bio, a Clinical Stage Biotechnology Company Focused on Therapeutics that Restore Immune Homeostasis, Announces CEO Transition

–Jodie Morrison appointed as Board Member and Acting CEO– Waltham, Mass. – September 20, 2022 — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced the appointment of Jodie Morrison as Board Member and Acting Chief Executive Officer, succeeding Michael Broxson. “Jodie has a deep background in executive, operational and […]

Q32 Bio and Horizon Therapeutics Announce Collaboration in Autoimmune Diseases

Waltham, Mass. and Dublin – August 15, 2022 — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Nasdaq: HZNP), today announced that they have entered into a collaboration and option agreement to develop ADX-914 for the treatment of autoimmune diseases. ADX-914 is a fully human anti-IL-7Rα antibody that re-regulates adaptive […]

Q32 Bio Presents New Preclinical Data at the International Society of Nephrology Frontiers Meeting Demonstrating the Therapeutic Potential of ADX-097

Data show that C3d-mediated tissue targeting of factor H results in potent, durable and efficacious local complement blockade without systemic complement inhibition Waltham, Mass. – June 23, 2022 — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced that the Company presented new preclinical data demonstrating the therapeutic potential of […]

Shelia Violette, Founder and Chief Scientific Officer of Q32 Bio, to Present at the Keystone Symposia “Resolution of Inflammation” Conference

Dr. Violette also organizing the “Tissue Fibrosis and Repair: Mechanisms, Human Disease and Therapies” conference at the Keystone Symposia Waltham, Mass. – June 8, 2022 — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced that its Founder and Chief Scientific Officer, Shelia Violette, Ph.D., will present “Targeting Complement in […]

Q32 Bio Initiates First-in-Human Phase 1 Clinical Study of ADX-097 for the Treatment of Complement Disorders

First clinical-stage program from Q32 Bio’s tissue targeted complement inhibitor platform Clinical-stage pipeline now consists of two programs in development to restore immune homeostasis Waltham, Mass. – May 26, 2022 — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced that dosing has been initiated in the healthy volunteer portion […]

Q32 Bio Presents Preclinical Data Highlighting the Design and Characterization of Lead Program for Innate Immunity, ADX-097, at the 28th International Complement Virtual Workshop 2021

C3d targeted fusion proteins enable highly specific tissue-targeted complement system inhibition ADX-097 has the potential to provide increased potency, decreased dosing frequency and improved safety in severe inflammatory and autoimmune diseases Cambridge, Mass. – December 13, 2021 — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced preclinical data for […]

Q32 Bio Presents Preclinical Data Supporting Next Generation Complement Inhibitor, ADX-097, at the American Society of Nephrology Kidney Week 2021

Data demonstrate ADX-097’s ability to precisely target complement blockade to diseased tissue In multiple renal disease models, ADX-097 potently inhibits disease-causing complement activation while avoiding systemic complement inhibition Cambridge, Mass. – November 8, 2021 — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced preclinical data from the Company’s lead […]

Q32 Bio to Present Preclinical Data on Next Generation Complement Inhibitor, ADX-097, at the American Society of Nephrology Kidney Week 2021

Cambridge, Mass. – October 18, 2021 – Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced that it will present preclinical data supporting the Company’s lead program for innate immunity, ADX-097, during an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2021, taking place virtually from November 4 […]

Q32 Bio Announces Appointment of Kathy LaPorte to its Board of Directors

Cambridge, Mass. – August 3, 2021 — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced the appointment of Kathy LaPorte to its Board of Directors. Ms. LaPorte, who brings over 30 years of experience in executive leadership and venture investing within the biotech industry, will serve as the Chair […]

Q32 Bio Appoints Adam Cutler as Chief Financial Officer

Cambridge, Mass. – July 7, 2021 — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced the appointment of Adam Cutler as Chief Financial Officer. Mr. Cutler will be responsible for all aspects of Q32’s financial strategy and operations.

Q32 Bio to Present at the Jefferies Virtual Healthcare Conference

Cambridge, Mass. – May 27, 2021 /PRNewswire/ — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced that Michael Broxson, Chief Executive Officer, will present a corporate overview at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 1:30 pm ET.

Q32 Bio Appoints Dr. Jason Campagna as Chief Medical Officer

Cambridge, Mass. (March 9, 2021) – Q32 Bio, a biotechnology company developing therapeutics to restore healthy immune regulation, today announced the appointment of Jason Campagna, M.D., Ph.D. as Chief Medical Officer. Dr. Campagna brings more than 15 years of biotech and pharmaceutical experience to the Q32 Bio executive team during a critical growth and development period for the company.

Q32 Bio Closes $60 Million Series B Financing, Advances to Clinical Stage Research in Therapeutics Designed to Restore Immune Homeostasis

Cambridge, Mass. (October 29, 2020) – Q32 Bio, a biotechnology company developing biologic therapeutics to restore healthy immune regulation, today announced the completion of a $60 million Series B financing co-led by OrbiMed Advisors and Acorn Bioventures. The company also announced the commencement of a Phase 1 clinical trial evaluating its best-in-class IL-7R antibody ADX-914, a significant milestone marking Q32 Bio’s entry into clinical-stage development.